64 related articles for article (PubMed ID: 6880903)
1. [A new surgical technic as a substitute for orchiectomy in the treatment of prostate cancer].
Romero Maroto J; Verdú Tartajo F
Actas Urol Esp; 1983; 7(1):7-16. PubMed ID: 6880903
[No Abstract] [Full Text] [Related]
2. [Surgical castration].
Kurihara J
Nihon Rinsho; 2000 Jul; 58 Suppl():183-5. PubMed ID: 11022710
[No Abstract] [Full Text] [Related]
3. Hormonal and pathologic changes after chemoablation of testes with hypertonic saline solution as a treatment method alternative to orchiectomy in patients with hormone sensitive metastatic prostatic cancer.
Emir L; Sunay M; Yalbuzdağ O; Karakaya Y; Erol D
Urol Oncol; 2011; 29(2):212-7. PubMed ID: 19272797
[TBL] [Abstract][Full Text] [Related]
4. The activity of epitestosterone in hormone dependent prostate tumour models.
Maucher A; von Angerer E; Hampl R; Stárka L
Endocr Regul; 1994 Mar; 28(1):23-9. PubMed ID: 7949009
[TBL] [Abstract][Full Text] [Related]
5. Endocrine treatment of prostate cancer: standard treatment and new perspectives.
Boccardo F; Pace M
In Vivo; 1993; 7(5):423-4. PubMed ID: 8110985
[TBL] [Abstract][Full Text] [Related]
6. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
Tsukamoto S; Akaza H
Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
[TBL] [Abstract][Full Text] [Related]
7. Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins.
Nickerson T; Miyake H; Gleave ME; Pollak M
Cancer Res; 1999 Jul; 59(14):3392-5. PubMed ID: 10416600
[TBL] [Abstract][Full Text] [Related]
8. Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate cancer.
Zhang XZ; Donovan MP; Williams BT; Mohler JL
Urology; 1996 Mar; 47(3):402-4. PubMed ID: 8633409
[TBL] [Abstract][Full Text] [Related]
9. Is pre-treatment testosterone a prognostic factor in prostate cancer?
Akumabor PN
Cent Afr J Med; 1993 Aug; 39(8):170-2. PubMed ID: 8020082
[TBL] [Abstract][Full Text] [Related]
10. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
[TBL] [Abstract][Full Text] [Related]
11. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A
Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
[No Abstract] [Full Text] [Related]
12. [Surgical castration for cancer of the prostate. A simplified technic].
Vallancien G
Ann Urol (Paris); 1988; 22(2):135-6. PubMed ID: 3289475
[TBL] [Abstract][Full Text] [Related]
13. Editorial comment on: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
Tombal B
Eur Urol; 2009 Feb; 55(2):321. PubMed ID: 18838209
[No Abstract] [Full Text] [Related]
14. Antiproliferative and antimetastatic effects of gossypol on Dunning prostate cell-bearing Copenhagen rats.
Chang CJ; Ghosh PK; Hu YF; Brueggemeier RW; Lin YC
Res Commun Chem Pathol Pharmacol; 1993 Mar; 79(3):293-312. PubMed ID: 8480076
[TBL] [Abstract][Full Text] [Related]
15. [Time-course of plasma testosterone in patients with prostate cancer treated by endocrine therapy].
Peyromaure M; Rebillard X; Ruffion A; Salomon L; Villers A; Soulie M;
Prog Urol; 2008 Jan; 18(1):2-8. PubMed ID: 18342148
[TBL] [Abstract][Full Text] [Related]
16. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Blackledge G; Kolvenbag G; Nash A
Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy for prostate cancer.
Bahnson R
J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
[No Abstract] [Full Text] [Related]
18. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
19. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
20. Re: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
Guess B; Scholz M
J Urol; 2001 May; 165(5):1644-5. PubMed ID: 11345950
[No Abstract] [Full Text] [Related]
[Next] [New Search]
